<SEC-DOCUMENT>0001214659-22-004220.txt : 20220322
<SEC-HEADER>0001214659-22-004220.hdr.sgml : 20220322
<ACCEPTANCE-DATETIME>20220322164304
ACCESSION NUMBER:		0001214659-22-004220
CONFORMED SUBMISSION TYPE:	PX14A6G
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20220322
DATE AS OF CHANGE:		20220322
EFFECTIVENESS DATE:		20220322

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ELI LILLY & Co
		CENTRAL INDEX KEY:			0000059478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				350470950
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		PX14A6G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-06351
		FILM NUMBER:		22760192

	BUSINESS ADDRESS:	
		STREET 1:		LILLY CORPORATE CTR
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285
		BUSINESS PHONE:		3172762000

	MAIL ADDRESS:	
		STREET 1:		LILLY CORPORATE CENTER
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LILLY ELI & CO
		DATE OF NAME CHANGE:	19941024

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Trinity Health Corp
		CENTRAL INDEX KEY:			0001769794
		IRS NUMBER:				351443425

	FILING VALUES:
		FORM TYPE:		PX14A6G

	BUSINESS ADDRESS:	
		STREET 1:		30555 VICTOR PARKWAY
		CITY:			LIVONIA
		STATE:			MI
		ZIP:			48152
		BUSINESS PHONE:		734-343-0916

	MAIL ADDRESS:	
		STREET 1:		30555 VICTOR PARKWAY
		CITY:			LIVONIA
		STATE:			MI
		ZIP:			48152
</SEC-HEADER>
<DOCUMENT>
<TYPE>PX14A6G
<SEQUENCE>1
<FILENAME>d322221px14a6g.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="trinity_logo.jpg" >&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTICE OF EXEMPT SOLICITATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NAME OF REGISTRANT: Eli Lilly &amp; Co. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NAME OF PERSON RELYING ON EXEMPTION: </B>Trinity Health</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ADDRESS OF PERSON RELYING ON EXEMPTION: </B>Catherine Rowan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&lt;rowancm@trinity-health.org&gt;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Gray 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Written materials are submitted pursuant to Rule 14a-6(g)(1) promulgated
under the Securities Exchange Act of 1934.&nbsp;Submission is not required of this filer under the terms of the Rule, but is made voluntarily.
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 63pt"><B>To:</B></TD><TD>Eli Lilly Shareholders</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 63pt"><B>Subject:</B></TD><TD STYLE="text-align: justify">Shareholder Proposal to Report Oversight of Risks Related to Anticompetitive Pricing Strategies</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 63pt"><B>Date:</B></TD><TD>March 22, 2021</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 63pt"><B>Contact:</B></TD><TD>Catherine Rowan, Director, Socially Responsible Investments, Trinity Health<BR>
&lt;rowancm@trinity-health.org&gt;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Trinity Health and co-filers Adrian Dominican Sisters, Bon Secours
Mercy Health, Friends Fiduciary Corporation, Mercy Investment Services and the Sisters of Charity of St. Elizabeth urge you to vote <B>FOR
Item 10</B>: &ldquo;Shareholder Proposal to Report Oversight of Risks Related to Anticompetitive Pricing Strategies&rdquo; (the &ldquo;Proposal&rdquo;)
which requests a Board report to shareholders on how it oversees risks related to anticompetitive practices, including whether the full
board or a board committee has oversight responsibility, whether and how consideration of such risks is incorporated into board deliberations
regarding strategy, and the board&rsquo;s role in the company&rsquo;s public policy activities related to such risks, at Eli Lilly&rsquo;s
annual general meeting on May 2, 2022. The full resolution asks:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>RESOLVED that shareholders of Eli Lilly and Company (&ldquo;Eli
Lilly&rdquo;) ask the board of directors to report to shareholders on how it oversees risks related to anticompetitive practices, including
whether the full board or board committee has oversight responsibility, whether and how consideration of such risks is incorporated into
board deliberations regarding strategy, and the board&rsquo;s role in Eli Lilly&rsquo;s public policy activities related to such risks.
The report should be prepared at reasonable expense and should omit confidential or proprietary information, as well as information about
existing litigation and claims of which Eli Lilly has notice.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Why should shareholders be concerned with anti-competitive practices
in the industry?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Anticompetitive practices can often push the limits of law and regulation
and have drawn significant scrutiny from federal regulators. The Food and Drug Administration has focused on promoting competition as
a way to moderate drug prices,<SUP>i</SUP> issuing a Drug
Competition Action Plan and policy guidance<SUP>ii</SUP>
and a Biosimilars Action Plan.<SUP>iii</SUP> Former FDA
Commissioner Scott Gottlieb complained at a roundtable on generic drugs that branded companies &ldquo;are exploiting loopholes in our
rules in ways that upset the careful balance between access and innovation.&rdquo;<SUP>iv</SUP>
Further, the Federal Trade Commission (FTC) has focused on curbing anti-competitive conduct in the pharmaceutical sector, with then acting
Chairwoman Rebecca Kelly Slaughter stating in May 2021 that &ldquo;[f]or decades, the FTC has challenged a number of illegal anticompetitive
practices in the pharmaceutical industry that can lead to high drug prices. The Commission should consider ways to build on this work
by addressing emerging and evolving practices that have the potential to harm consumers [and] . . . when investigating potentially anticompetitive
conduct, we should consider the full breadth of the FTC Act&rsquo;s prohibition on unfair methods of competition.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The proponents believe strategies to expand monopolies, through such
anticompetitive practices such as pay-for-delay, product hopping, evergreening of patents, pricing collusion, etc. without any meaningful
new science or invention do not help create long-term value for the company or for shareholders. More importantly, it exacts a heavy cost
on health systems and communities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Engaging in such practices presents legal, financial, regulatory
and reputational risks that, unmanaged, may threaten a company&rsquo;s social license to operate. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Why should shareholders be concerned with anti-competitive practices
at Eli Lilly?</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">A three-year investigation on drug pricing by the US House Committee on Oversight
and Reform, released in December 2021, found that Eli Lilly and other pharmaceutical companies &ldquo;use patent protections and market
exclusivities granted by the FDA to suppress generic competition.&rdquo; It also noted Eli Lilly along with Novo Nordisk and Sanofi control
around 90% of the insulin market in the United States. The report described &ldquo;internal documents [that] show the three largest insulin
manufacturers raised their prices in lockstep in order to maintain &lsquo;pricing parity&rsquo; and that senior executives encouraged
this practice.&rdquo; A chart in the report indicates how Eli Lilly and Novo Nordisk practiced &lsquo;shadow pricing&rsquo; in raising
their rapid-acting insulin products Humalog and NovoLog, from at least 2008 to 2018. From 1996-2017 &ldquo;Eli Lilly raised the price
of its 10mL vial of Humalog subcutaneous solution a total of 34 times for a cumulative price increase of more than 1,200%&rdquo;. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #111111">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">The House report states that after biosimilar competition to Humalog was
introduced in 2018, Eli Lilly introduced an authorized generic version of Humalog in 2019 (at $137 vial, compared to Humalog&rsquo;s $275)
and has not raised Humalog&rsquo;s price since. <FONT STYLE="color: #111111; background-color: white">Unlike true generics, which are
produced by competing drug companies, authorized generics are sold by the original manufacturer at a discounted price. &nbsp;The authorized
generic has marketing exclusivity until the original brand drug loses its patent, which means the drug maker maintains its monopoly for
that drug.</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">T1 International, an organization led by people with or impacted by Type
1 diabetes that advocates for access to insulin has found this authorized generic version is still unaffordable -even with a second price
reduction of the generic version, to $80. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Legislative, regulatory and legal risks facing Lilly and its pricing
of insulin</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Eli Lilly states in its 2021 Form 10-K: &ldquo;<FONT STYLE="background-color: white">Additional
policies, regulations, legislation, or enforcement, including as a result of the regulatory priorities of the current U.S. presidential
administration and other regulatory authorities worldwide, could adversely impact our business and revenue. For example, pending legislation
in the U.S. could result in government negotiation of the price of some of our medicines, including insulin.&rdquo;</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">President Biden, in his March 2022 State of the Union address, urged Congress
to reduce the out-of-pocket insurance cost of insulin to $35 a month. The American Diabetes Association and The Endochrine Society endorsed
the cap. The President called on Congress to give Medicare the power to negotiate with drug companies for lower prices. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">The 10-K reports that Eli Lilly has received subpoenas from 2 state attorneys
general and civil investigative demands from 3 other state attorneys general offices about the sale and pricing of insulin products. In
early 2022 The Michigan State Attorney General was granted court approval to investigate Eli Lilly&rsquo;s insulin pricing practices,
under Michigan&rsquo;s consumer protection law. Harris County, Texas is moving forward with a lawsuit against several drug manufacturers,
including Eli Lilly, and pharmacy benefit managers for conspiring to inflate the price of insulin.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>We are concerned that these strategic risks
are not fully addressed by Eli Lilly&rsquo;s board of directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Lilly&rsquo;s Statement in Opposition to the proposal does not mention anticompetitive
practices or risks related to competition, nor does it discuss risks related to specific anticompetitive practices relevant to Lilly such
as pricing collusion. Instead, Lilly points to information in the proxy statement and on the ESG page of its website about decision-making
around pricing and actions it has taken to address pricing and access concerns under board oversight. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Eli Lilly has not disclosed any information as to how the Board oversees
risks related to anti-competitive practices or competition-related risk, which is the essential objective of the Proposal. Eli Lilly&rsquo;s
board should be able to demonstrate to shareholders that it has applied rigorous oversight, with clear criteria, expectations and regular
review, to management decisions about pricing, patents, and innovation. Boilerplate or vague language about general strategic oversight
is not sufficient in light of intensive regulatory scrutiny over practices both within the US and abroad. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>We therefore
urge shareholders to vote FOR Item 10 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>i</SUP></FONT>
<U>See</U> Transcript of Public Meeting, U.S. Food and Drug Administration, &ldquo;The Hatch-Waxman Amendments: Ensuring a Balance Between
Innovation and Access,&rdquo; July 18, 2017, at p.11 (available at https://www.fda.gov/media/107217/download)
(then-Commissioner Gottlieb stating at a public meeting/roundtable on speeding access to generic drugs that FDA wants to &ldquo;make sure
that, in places where Congress intended for there to be vigorous drug competition, such competition actually reaches the market&rdquo;
and that the FDA has a role to play in bringing down drug prices by &ldquo;encouraging competition&rdquo;)(hereinafter, &ldquo;the Transcript).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>ii</SUP></FONT>
Press Release, U.S. Food and Drug Administration, &ldquo;FDA Tackles Drug Competition to Improve Patient Access,&rdquo; June 27, 2017
(https://www.fda.gov/news-events/press-announcements/fda-tackles-drug-competition-improve-patient-access).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>iii</SUP></FONT>
<I><U>See</U></I> U.S. Food and Drug Administration, &ldquo;Biosimilars Action Plan: Balancing Innovation and Competition,&rdquo; July
2018 (https://www.fda.gov/media/114574/download).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>iv</SUP></FONT>
Transcript, at p.15.</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2px solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>trinity_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trinity_logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (   $Q  (    0    3@
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
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M11BND8\J\D?@9X\\&_&JWM[*Z^(/AKQN;?1[(Z=9:IK>EW]Q':V$<LDR6?\
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MU#3=;\#^%]<U?6]*N[;]['?6-SX)?4M4LKBW(WQW%N8Y(V&5<$5^PW_!/O\
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M^V!KO['/_!-;]LGXSZ?H=L/B7K/[5]_X+\%:3?LMWIND^/\ Q=X/\/RK=:D
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M:PU"VA3[-JLEI8W-Y';Z5K.E6FEZGI>JWEQJ,]C:?(__  5[_;Z\ _M<^ /
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M9%/(-?%O_!5__@G/H'[??P,\C0XTTSX]?"^SU_6_@[KYFAM;74KZ]M[:74O
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>%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
